Product Information
AMIODARONE HCL 400 MG TABLET is a generic product labeled by Advagen Pharma Ltd., priced at $0.4996 per EA under NDC 72888006130. Its NADAC has been published 265 times since Sep 8, 2021.
FDA first approved this application on Nov 6, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888006130
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMIODARONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078578FDA Approved
11/6/2008
TE Code
AB
On Market Since
8/21/2020
Pharmacological Classes
Price Statistics
The NADAC for AMIODARONE HCL 400 MG TABLET has been published 265 times since Sep 8, 2021, and over the history we have for it it has declined 71.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4996 per EA |
|---|---|
| All-time high | $3.0563 (Apr 13, 2022) |
| All-time low | $0.2214 (Aug 21, 2024) |
| 52-week high | $0.4996 |
| 52-week low | $0.3410 |
| Median price | $0.5213 |
| Average price | $1.0198 |
| Largest weekly change | -74.0% (Mar 20, 2024) |
| Weeks tracked | 265 |
| Tracking since | Sep 8, 2021 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amiodarone Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMIODARONE HCL 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for AMIODARONE HCL 400 MG TABLET, manufactured by Advagen Pharma Ltd., is $0.4996 per EA (NDC 72888006130), effective Sep 30, 2026.
How has the price of AMIODARONE HCL 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for AMIODARONE HCL 400 MG TABLET has declined 71.0%. It has been tracked across 265 weekly CMS publications since Sep 8, 2021.
What are the highest and lowest recorded NADAC prices for AMIODARONE HCL 400 MG TABLET?
Since Sep 8, 2021, the NADAC for AMIODARONE HCL 400 MG TABLET has ranged from a low of $0.2214 (Aug 21, 2024) to a high of $3.0563 (Apr 13, 2022), with a median of $0.5213 per EA.
Are there cheaper alternatives to AMIODARONE HCL 400 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as AMIODARONE HCL 400 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures AMIODARONE HCL 400 MG TABLET?
AMIODARONE HCL 400 MG TABLET (NDC 72888006130) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.